Align Technology Reports Third Quarter 2026 Financial Results
Align Technology, Inc. reported third-quarter 2026 revenue of $1.015 billion and adjusted earnings per share of $2.80, both exceeding analyst expectations.
Stocks · News reference
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Align Technology Issues Fourth Quarter 2026 Revenue Guidance
Align Technology, Inc. provided revenue guidance for the fourth quarter of 2026, projecting a range between $1.00 billion and $1.02 billion.
Align Technology Announces CEO Succession Plan
Align Technology, Inc. has appointed Jennifer L. Davis as its next President and Chief Executive Officer, effective December 31, 2026, succeeding current CEO Joseph M. Hogan.
UBS Adjusts Price Target on Align Technology to $186 From $205, Maintains Neutral Rating
UBS has lowered its price target for Align Technology, Inc. while keeping a Neutral rating on the stock.
Roth Capital Initiates Coverage on Dianthus Therapeutics With Buy Rating
Roth Capital has initiated research coverage on Dianthus Therapeutics, assigning the biotechnology company a Buy rating.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.